Phathom Pharmaceuticals, Inc. (PHAT)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation

Ask a question about Phathom Pharmaceuticals, Inc. (PHAT)

Company Performance

Current Price

as of Oct 16, 2024

$16.47

P/E Ratio

N/A

Market Cap

$1.12B

Description

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Metrics

Overview

HQFlorham Park, NJ
SectorHealth Technology
IndustryPharmaceuticals: Major
TickerPHAT
Price$16.47+5.17%

Trading Information

Market Cap$1.12B
Float54.93%
Average Daily Volume (1m)948,482
Average Daily Volume (3m)932,931
EPS-$5.13

Company

Revenue$9.92M
Rev Growth (1yr)N/A
Net Income-$91.45M
Gross Margin81.21%
EBITDA Margin-1,052.74%
EBITDA-$77.10M

EV$833.29M
EV/Revenue84.02
P/EN/A
P/S97.24
P/BN/A

Documents

Earnings Calls

Earnings Report 2024Q2

Earnings Report 2024Q1

Earnings Report 2023Q4

Factset Street Account

Phathom Pharmaceuticals reports Q3 EPS ($0.76) vs FactSet ($0.89) [7 est, ($1.11)-(0.65)] ($7.82, 0.00) (2023-11-09T13:10:37Z)

Phathom Pharmaceuticals announces FDA approval of VOQUEZNA (vonoprazan) tablets for the treatment of erosive GERD and relief of heartburn associated with erosive GERD in adults ($9.61, 0.00) (2023-11-01T21:02:48Z)

Phathom Pharmaceuticals announces commercial availability of VOQUEZNA (vonoprazan) tablets ($7.22, 0.00) (2023-11-28T13:05:00Z)

Phathom announces FDA approval of reformulated Vonoprazan tablets for VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK for the treatment of H. pylori Infection in adults ($8.66, 0.00) (2023-10-30T12:04:05Z)